Valeant

Valeant Recent News

Bill Ackman Is Killin' It In Chipotle
|
Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook
|
Valeant's Post-Ackman Recovery Is Characterized By 'Less Money, More Problems'
|
Valeant: Traders Vs. Portfolio Managers
|
Pershing Square Defends Valeant's Progress, Can't Defend Its Stock Performance
|
Valeant's Asset Sale To L'Oreal Explained
|
Valeant's Laundry List: Products, Divestitures And Debt Load
|
Valeant Shares Carry Too Much Risk To Be Recommended As An Investment: Wells Fargo
|
Bill Ackman's Pershing Square Releases Q3 Letter To Shareholders
|
Criminal Charges Against Former Valeant Exec 'Not Pertinent But Underscores Cautious Outlook'
|
Is Allergan Going After Valeant's Eye Surgery Assets?
|
Analysts Having Difficulty Getting Comfortable With Valeant's Fundamentals
|
What Did Valeant Look Like Last Time The Stock Was Under $15?
|
A Deeper Look Into Valeant's Assets As It Searches For Salix Buyer
|
Valeant's Salix Story: To Sell Or Not To Sell?
|
Ackman: Valeant Doesn't Have To Sell Core Assets
|
Valeant Management On Q1 Call: 'We Don't Feel We Can Accurately Predict' GAAP Earnings
|
Can Broadcom Or Medtronic Offer Up An Earnings Surprise?
|
Report: Valeant Rejected A Takeover Offer Prior To Hiring Papa As CEO
|
Piper Jaffray Analyst: Latest Report On Valeant 'Doesn't Surprise Me'
|
Valeant's Price Cut To Hospitals Just Lip Service?
|
Ackman: Valeant Made Some Mistakes, But It's Not A Sewer
|
Senator Calls Out Bill Ackman, Questions His Senate Hearing Comments On Drug Pricing
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved